据了解，海菲曼主要从事自主品牌"HIFIMAN"终端电声产品的设计、研发、生产和销售。公司北交所 IPO于2024年12月30日获得受理，2025年1月23日进入问询阶段。本次冲击上市，公司拟募集资金约4.3 亿元。 北京商报讯（记者 马换换 王蔓蕾）近日，北交所官网显示，昆山海菲曼科技集团股份有限公司（以下 简称"海菲曼"）IPO上会获得通过。 在上市委会议现场，上市委要求海菲曼结合同行业可比公司情况，进一步说明公司竞争优势与核心竞争 力。另外，上市委还要求海菲曼结合公司主要产品生产工艺流程、发展历程，说明报告期内收购多家标 的公司的背景、必要性及合理性。 ...

Group 1: IPO Review and Approval - This week, the Beijing Stock Exchange (BSE) concluded its IPO review, with 3 companies undergoing scrutiny and 2 successfully passing the review [2] - Yongda Co., Ltd. became the first project this year to have its IPO review postponed, raising market concerns due to ongoing issues regarding the sustainability of its performance and the rationality of its fundraising projects [2] - Yongda has adjusted its fundraising plans twice during the review process, eliminating a liquidity support project and reducing the proposed investment scale for its "Heavy Chemical Equipment Production Base Phase I" project, adding uncertainty to its review [2] Group 2: Companies Approved for IPO - Kunshan Haifiman Technology Group Co., Ltd. was approved for IPO, specializing in high-end audio products under the brand "HIFIMAN," with projected revenues of 1.54 billion yuan in 2022 and a net profit of 360 million yuan [3] - Dalian Meidele Industrial Automation Co., Ltd. also received approval, focusing on intelligent manufacturing equipment, with revenues of 10.31 billion yuan in 2022 and a net profit of 2.22 billion yuan [4] Group 3: Newly Listed Companies - Hai'an Group officially listed on the Shenzhen Stock Exchange, opening with a surge of over 68%, closing at 83.52 yuan per share, with a total market value of 15.532 billion yuan [5] - Innovation Industry, an electrolytic aluminum company, debuted on the Hong Kong Stock Exchange with a first-day increase of 32.76%, focusing on alumina refining and electrolytic aluminum smelting [6] - Nant Technology saw a significant first-day increase of 183.03% on the BSE, closing at 24.51 yuan per share [7] Group 4: Companies Filing for IPO - Kewang Pharmaceutical, founded in 2017, focuses on tumor immunotherapy with a pipeline of 7 major assets, including the core product ES102, which is in clinical development [11] - Mingyu Pharmaceutical, established in 2018, has a core pipeline in the tumor field, including ADC and dual-target antibodies, with a recent valuation of 3.936 billion yuan after a financing round [12] - Baoji Pharmaceutical, founded in 2019, specializes in recombinant biopharmaceuticals and is in the clinical stage with its core pipeline KJ017, aimed at treating complex diseases [13]

人民财讯11月28日电，北交所上市委员会于11月28日召开2025年第37次审议会议，海菲曼成功过会。其 本次拟北交所上市募集资金4.3亿元，保荐人为申港证券。海菲曼是高端电声品牌商，主要从事自主品 牌"HIFIMAN"终端电声产品的设计、研发、生产和销售。 ...

Core Viewpoint - The company, Kunshan HIFIMAN Technology Group, is preparing for an IPO on the Beijing Stock Exchange, showcasing strong financial performance and a focus on high-end audio products with significant international market presence [1][2]. Financial Performance - In 2024, the company reported a total revenue of 226 million yuan, representing a year-on-year growth of 11.18% - The net profit reached 68.97 million yuan, with a year-on-year increase of 24.27% - Basic earnings per share stood at 1.79 yuan, and the gross profit margin was 70.10% [1]. Market Presence - The company has seen rapid growth in overseas markets, with overseas revenue accounting for 72.85% in 2021, 67.94% in 2022, 66.26% in 2023, and 61.23% in the first half of 2024 - Key markets include the United States, Europe, Japan, and South Korea, with a focus on high-end audio products [2]. Competitive Strategy - HIFIMAN targets the high-end market through a strategy that integrates technology, culture, and operations - The company competes with brands like Sennheiser and Audio-Technica in premium audio retail locations, with high-end models priced over $2,000 making up 35% of sales [2]. Market Share - According to 2024 statistics, HIFIMAN holds a 16.26% market share in the $250-$500 price range, 36.59% in the $500-$1,000 range, and 23.44% in the $1,000-$2,000 range on Amazon in the U.S. [2]. Future Development - The company has outlined two strategic directions: "deep technological breakthroughs" and "extension of application scenarios" - Plans include strengthening research in electroacoustic technology and exploring cross-industry applications in health monitoring and smart home technologies [3].